the LEADER trial showed cardiovascular benefit in high-risk diabetic patients
Weight loss doesnt stop completely but slows to minimal weekly changes
Saxenda for weight management), and exenatide (Byetta, Bydureon for diabetes)
Patients seeking support for obesity or weight-related health conditions are encouraged to speak with their GP or a specialist weight management service to explore currently available, evidence-based treatments
An important question to ask, and one we may never have a clear answer to, is what amount of residual gastric contents increases the risk of aspiration? Surely, type of gastric contents (liquid or solid) also matters
Of course, more receptors also mean careful management dosing has to be titrated to minimize side effects, and well learn from ongoing trials if certain patient groups respond better than others